The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal discomfort
MASH affects around 14.9 million adults in the U.S., or roughly 6% of the population, and its prevalence is on the rise
Recent clinical data shows that GLP-1 receptor agonists like semaglutide can reduce cholesterol levels while promoting weight loss, offering a two-pronged approach to cardiovascular health
Since the FDA ruled theres no longer a shortage of semaglutide and tirzepatide, compound pharmacies increasingly rely on custom doses and formulations, such as mixing the medication with vitamins or using new pills or tinctures
An additional study compared weight loss outcomes for semaglutide and tirzepatide but used data specifically for these medications labeled for T2DM and thus included a large (52%) proportion of patients with T2DM
Kumar et al 2017